




J. Torrent Pou, S. Jornet Montaña, L. Sánchez-Pacheco Tardón, L. Sánchez Parada, L. Castillo Palomares, L. Canadell Vilarrasa, M. Vuelta Arce, M. Canela Subirada.
Pharmacy Service, Hospital Universitari Joan XXIII, Tarragona, Spain.

Purpose

To describe and analyze the use of Tolvaptan in a third level hospital.

Materials and Methods



Results

Patient	Age	Sex	Initial Dosage	Maintenance Dosage	Treatment duration	Background pathology	Cause & Clinical department prescriber	[Na] initial mEq/L	SIADH	End of Treatment Reason
Patient 1	54	Male	15 mg/ day	30 mg/ day	15	Liver carcinoma	Ascitis. Dilutional Hyponatremia. (Digestive)	120	No	Death
Patient 2	72	Male	15 mg/ day	30 mg/ day	105	Heart Failure	No response to diuretics. Anasarca. (Cardiology)	129	No	Death
Patient 3	72	Male	30 mg/ day	30 mg/ day	18	Heart Failure	No response to diuretics. Anasarca. (Cardiology)	129	No	Death
Patient 4	80	Male	30 mg/ day	30 mg/ day	85	Heart Failure	No response to diuretics. Anasarca. (Cardiology)	137	No	Treatment still in progress

Patient	Cost-Day Average/ Patient	Days Treatment	Cost per Patient
Patient 1	88,32€	15	1.324,80€
Patient 2		105	9.273,60€
Patient 3		18	1.589,70€
Patient 4		85	7.507,20€

Conclusions

In our hospital, Tolvaptan was not used for approved indication (Treatment of adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion –SIADH–) in any of the patients and for all them it was processed as compassionate use (out of label). We do not have enough data to evaluate the efficacy of this treatment in these patients. The high cost of the treatment and the little experience in its use require strict control in its administration.

Conflict of interest: None